In a trial assessing the efficacy of cediranib combined with standard treatment in newly diagnosed glioblastoma patients, increased plasma protein levels of sVEGFR-1 and IL-8, after, respectively, 29 and 48 days of treatment, were associated with reduced PFS [12]. Here, CXCL8 is linked to glioblastoma.